Janux Therapeutics, a clinical-stage biopharmaceutical company, has been upgraded to Strong Buy due to its solid cash position and validated technology platforms. The company discontinued its JANX008 program to focus resources on higher-potential assets, demonstrating financial discipline. Strategic partnerships with Merck and Bristol-Myers Squibb could bring up to $1.8 billion in milestone payments plus royalties, supporting long-term value creation. Despite risks from its early-stage pipeline and potential near-term volatility, Janux's cash runway and platform progress make it a high-risk, long-term investment opportunity.
Basel Medical Group Ltd announced it has regained compliance with Nasdaq's minimum bid price rule after its share price stayed at or above $1.00 for 10 consecutive business days ending July 7, 2026. The company was previously notified in January 2026...
The global wax market, valued at $11.26 billion in 2025, is projected to grow to $16.65 billion by 2035 at a CAGR of 3.99%. Growth is fueled by rising demand in packaging, cosmetics, candle making, adhesives, and industrial uses, with natural waxes l...
BingX, a major crypto exchange, introduced the BingX Visa Debit Card in partnership with Wirex, allowing users to spend digital assets globally through Visa's payment network. The card supports purchases, ATM withdrawals, and automatic currency conve...
Backpack has introduced the first-ever 24/7 trading platform for real U.S. equities, allowing international investors to buy and sell stocks like SpaceX, Micron, and SanDisk around the clock. Unlike synthetic derivatives, these are actual equities wi...
Independent proxy advisory firms, including ISS, recommend Equinox Gold shareholders vote in favor of the proposed merger with Orla Mining, which aims to create a leading North American gold producer. The combined company is expected to produce 1.1 m...
